8-K: Walgreens Boots Alliance to Be Acquired by Sycamore Partners in Deal Valued Up to $23.7 Billion

Walgreens Boots Alliance (WBA) has entered into a definitive agreement to be acquired by Sycamore Partners for a total consideration of up to $23.7 billion, including cash and potential future payments from the monetization of VillageMD businesses.

Summary

• Walgreens Boots Alliance (WBA) has agreed to be acquired by Sycamore Partners.
• The total transaction value is up to $23.7 billion.
• WBA shareholders will receive $11.45 per share in cash at closing.
• Shareholders will also receive a non-transferable right (DAP Right) to receive up to an additional $3.00 per share from the future monetization of WBA's debt and equity interests in VillageMD, Summit Health, and CityMD businesses (Divested Assets).
• The Cash Consideration represents a premium of 29%, and the Total Consideration represents a premium of up to 63%, to the WBA closing share price of $8.85 on December 9, 2024.
• The transaction is expected to close in the fourth quarter of calendar year 2025.
• Sycamore has received fully committed financing for the transaction.
• Stefano Pessina and his holding company, owning approximately 17% of WBA's shares, will vote in favor of the transaction and reinvest their Cash Consideration into the acquiring company.
• A Divested Assets Committee will determine the process to maximize the value of WBA's interests in the Divested Assets.
• WBA expects to receive 100% of the initial net proceeds from any sale of the Divested Assets up to the amount of debt owed by VillageMD, which is $3.4 billion as of February 28, 2025, accruing PIK interest at 19% per year.
• DAP Right holders will be entitled to 70% of any net proceeds received by WBA from the sale of the Divested Assets.
• The maximum amount payable to DAP Right holders is $3.00 per DAP Right or approximately $2.7 billion in the aggregate.
• WBA will release its fiscal year 2025 second quarter financial results on April 8, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the acquisition premium and potential for future value creation through the DAP Rights. However, uncertainties surrounding the monetization of the Divested Assets and the risks associated with the transaction temper the overall sentiment.

Positives

• Shareholders receive a premium for their shares, with the potential for additional value through the DAP Rights.
• Sycamore Partners has a strong track record of successful retail turnarounds.
• The transaction provides WBA with the expertise and experience needed to navigate the challenges of the pharmacy industry.
• The transaction is not subject to a financing condition, increasing the likelihood of completion.
• Stefano Pessina's reinvestment demonstrates confidence in the future of the business.

Negatives

• The additional $3.00 per share is contingent on the successful monetization of the Divested Assets, which is not guaranteed.
• The DAP Rights are non-transferable, limiting shareholders' flexibility.
• The transaction will result in WBA becoming a private company, delisting from the Nasdaq Stock Market.
• There is a risk that the holders of Divested Asset Proceed Rights will receive less-than-anticipated payments or no payments with respect to the Divested Asset Proceed Rights after the closing of the proposed transaction and that such rights will expire valueless.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Sycamore Partners may fail to obtain the necessary financing arrangements.
• The transaction may not receive the required regulatory approvals or stockholder approval.
• An event, change, or circumstance could lead to the termination of the transaction agreements.
• The announcement or pendency of the transaction could negatively impact WBA's business relationships and operations.
• WBA may face difficulties retaining key personnel and maintaining relationships with business partners.
• The transaction could result in significant or unexpected costs, charges, or expenses.
• Potential litigation could be instituted against the parties involved in the transaction.
• Uncertainties related to the continued availability of capital and financing and rating agency actions could arise.
• Restrictions during the pendency of the transaction may impact WBA's ability to pursue certain business opportunities.
• Adverse general and industry-specific economic and market conditions could negatively impact the transaction.

Future Outlook

The company anticipates closing the transaction in the fourth quarter of calendar year 2025, subject to customary closing conditions, including shareholder and regulatory approvals. WBA aims to become the first choice for pharmacy, retail, and health services.

Management Comments

• Tim Wentworth, Chief Executive Officer, Walgreens Boots Alliance, said, 'While we are making progress against our ambitious turnaround strategy, meaningful value creation will take time, focus and change that is better managed as a private company.'
• Stefan Kaluzny, Managing Director of Sycamore Partners, said, 'This transaction reflects our confidence in WBAs pharmacy-led model and essential role in driving better outcomes for patients, customers and communities.'

Industry Context

This announcement reflects the ongoing trend of private equity firms acquiring established retail and healthcare companies to drive operational improvements and strategic shifts away from the pressures of the public market. Sycamore Partners' expertise in retail turnarounds suggests a focus on streamlining operations and enhancing WBA's market position.

Comparison to Industry Standards

• Similar transactions in the retail pharmacy space include CVS's acquisition of Aetna, which aimed to integrate pharmacy and health insurance services.
• Private equity firms like Sycamore Partners often target companies with strong brand recognition but underperforming operations, similar to their acquisition of Staples in 2017.
• The premium offered to WBA shareholders is comparable to other recent take-private deals in the retail sector, reflecting the value of established brands and customer loyalty.

Stakeholder Impact

• Shareholders will receive a premium for their shares and potential future value through DAP Rights.
• Employees may experience changes as Sycamore Partners implements its turnaround strategy.
• Customers and patients can expect continued service under the Walgreens and Boots brands.
• Communities will continue to be served by WBA, with the goal of positively impacting health outcomes.
• Suppliers and creditors will be impacted by the change in ownership and potential operational changes.

Next Steps

• WBA will file a definitive proxy statement on Schedule 14A with the SEC.
• The Company and certain affiliates will jointly file a transaction statement on Schedule 13E-3.
• WBA shareholders will vote on the proposed transaction.
• The transaction is subject to customary closing conditions, including regulatory approvals.
• The Divested Assets Committee will determine the process to maximize the value of WBA's interests in the Divested Assets.

Key Dates